My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

131.06 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
49 50 Next >
Is Novartis a Good Stock to Buy Right Now?
The multinational pharma giant excels as an income play. 
Via The Motley Fool
Veterinary Healthcare Product Market to See Huge Growth : Pfizer, Merck, Johnson & Johnson
Stay up-to-date with Veterinary Healthcare Product Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Looking At Novartis's Recent Unusual Options Activity
 
Via Benzinga
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin 
Via MarketBeat
Topics Death
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
  
Via Benzinga
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
Eylea sales fell and missed expectations in the U.S. 
Via Investor's Business Daily
Is This Big Pharma Stock a Buy for Dividend Investors?
The Swiss pharmaceutical giant possesses a tremendous product pipeline. 
Via The Motley Fool
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
Smokeless Tobacco Treatment Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies),... 
Via SBWire
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Why Novartis Stock Is Trading Higher Today
 
Via Benzinga
Earnings Preview: Novartis
 
Via Benzinga
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program... 
Via Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor... 
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS). 
Via InvestorPlace
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth. 
Via MarketBeat
Topics Economy
Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis
Get Oral Cancer Treatment Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise
Stay up-to-date with AI for Pharma and Biotech Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Artificial Intelligence
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
 
Via Benzinga
What's Going On With Immix Biopharma Stock Today
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG' 
Via Benzinga
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several... 
Via Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels
Novartis AG (NYSE: NVS) released detailed  
Via Benzinga
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam. 
Via Benzinga
Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise
Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations. 
Via Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment
 
Via Benzinga
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.